INCY Stock Down on Disappointing Skin Disease Study Data

Shares of Incyte (INCY) were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis suppurativa (HS).HS, a chronic inflammatory skin condition, is characterized by painful nodules and abscesses.While both the late studies STOP-HS1 and STOP-HS2 studies met their primary endpoint, the results lagged investor expectations, and consequently, shares declined.Shares of Incyte have lost 7.2% in the pa ...